Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) EV/Sales Ratio: 3.00x

Is Charles River Laboratories International, Inc.’s EV/Sales ratio high or low?

Charles River Laboratories International, Inc.'s EV/Sales ratio of 3.00x is 21% below its 5-year average of 3.79x, near the low end of its 5-year range (1.88x–8.04x).

As of Friday, June 12, 2026. 7.40% above its 12-month average of 2.79x.

CRL EV/Sales Ratio Chart

CRL EV/Sales Ratio
3.00x+15.38% 1Y
Zoom

CRL Average EV/Sales Ratio Chart

CRL Current vs Average EV/Sales Ratio Chart

CRL EV/Sales Ratio Metrics

EV/SALES RATIO

3.00x

EV/SALES RATIO AVG TTM

2.79x

EV/SALES RATIO AVG 3Y

3.02x

EV/SALES RATIO AVG 5Y

3.79x

EV/SALES RATIO AVG 10Y

3.80x

EV/SALES RATIO AVG 15Y

3.40x

EV/SALES RATIO AVG 20Y

3.23x

CURRENT VS TTM AVG

+7.40%

CURRENT VS 3Y AVG

-0.80%

CURRENT VS 5Y AVG

-20.88%

CURRENT VS 10Y AVG

-21.01%

CURRENT VS 15Y AVG

-11.80%

CURRENT VS 20Y AVG

-7.04%

CRL Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Charles River Laboratories International, Inc. (CRL)$9.06B3.00x2.79x3.02x3.79x
Tempus AI, Inc. (TEM)$8.65B6.72x11.47x12.18x12.18x
Bio-Rad Laboratories, Inc. (BIO)$7.91B3.38x3.41x3.67x4.57x
Baxter International Inc. (BAX)$10.70B1.61x1.72x2.17x2.64x
Hims & Hers Health, Inc. (HIMS)$6.44B3.17x4.73x4.20x4.27x
Align Technology, Inc. (ALGN)$12.64B2.85x2.73x4.07x5.91x
Solventum Corporation (SOLV)$13.72B2.23x2.19x2.26x2.26x
Hologic, Inc. (HOLX)$16.97B4.25x4.02x4.39x4.15x
23andMe Holding Co. (ME)$15.31M0.02x0.35x0.71x3.53x
Moderna, Inc. (MRNA)$19.70B8.54x5.96x5.02x6.82x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Charles River Laboratories International, Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Charles River Laboratories International, Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The EV/Sales ratio for CRL stock is 3.00x.
Is Charles River Laboratories International, Inc.'s EV/Sales ratio high or low?
Charles River Laboratories International, Inc.'s EV/Sales ratio of 3.00x is 21% below its 5-year average of 3.79x, near the low end of its 5-year range (1.88x–8.04x).
What is the TTM average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The TTM average EV/Sales ratio for CRL stock is 2.79x.
What is the 3Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The 3Y average EV/Sales ratio for CRL stock is 3.02x.
What is the 5Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The 5Y average EV/Sales ratio for CRL stock is 3.79x.
What is the 10Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The 10Y average EV/Sales ratio for CRL stock is 3.80x.
What is the 15Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The 15Y average EV/Sales ratio for CRL stock is 3.40x.
What is the 20Y average EV/Sales ratio for Charles River Laboratories International, Inc. (CRL)?
The 20Y average EV/Sales ratio for CRL stock is 3.23x.

Charles River Laboratories International, Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-113.00x
2026-06-102.98x
2026-06-093.02x
2026-06-082.98x
2026-06-052.92x
2026-06-042.97x
2026-06-032.90x
2026-06-022.84x
2026-06-012.92x
2026-05-292.91x
2026-05-282.92x
2026-05-272.71x
2026-05-262.62x
2026-05-222.66x
2026-05-212.64x
2026-05-202.61x
2026-05-192.56x
2026-05-182.53x
2026-05-152.54x
2026-05-142.65x
2026-05-132.69x
2026-05-122.76x
2026-05-112.76x
2026-05-082.87x
2026-05-072.92x
2026-05-062.94x
2026-05-052.98x
2026-05-042.82x
2026-05-012.74x
2026-04-302.76x
2026-04-292.72x
2026-04-282.75x
2026-04-272.81x
2026-04-242.79x
2026-04-232.77x
2026-04-222.98x
2026-04-212.95x
2026-04-202.98x
2026-04-172.96x
2026-04-162.88x
2026-04-152.92x
2026-04-142.91x
2026-04-132.90x
2026-04-102.86x
2026-04-092.86x
2026-04-082.86x
2026-04-072.79x
2026-04-062.77x
2026-04-022.84x
2026-04-012.85x
2026-03-312.82x
2026-03-302.67x
2026-03-272.66x
2026-03-262.73x
2026-03-252.74x
2026-03-242.66x
2026-03-232.65x
2026-03-202.59x
2026-03-192.59x
2026-03-182.64x
2026-03-172.59x
2026-03-162.57x
2026-03-132.62x
2026-03-122.58x
2026-03-112.78x
2026-03-102.76x
2026-03-092.88x
2026-03-062.85x
2026-03-052.93x
2026-03-042.91x
2026-03-032.86x
2026-03-022.90x
2026-02-272.90x
2026-02-262.86x
2026-02-252.76x
2026-02-242.75x
2026-02-232.71x
2026-02-202.78x
2026-02-192.72x
2026-02-182.65x
2026-02-172.55x
2026-02-132.58x
2026-02-122.55x
2026-02-112.64x
2026-02-102.83x
2026-02-092.88x
2026-02-062.93x
2026-02-052.86x
2026-02-043.08x
2026-02-033.08x
2026-02-023.22x
2026-01-303.19x
2026-01-293.20x
2026-01-283.27x
2026-01-273.30x
2026-01-263.33x
2026-01-233.30x
2026-01-223.35x
2026-01-213.39x
2026-01-203.28x
2026-01-163.30x
2026-01-153.35x
2026-01-143.26x
2026-01-133.29x
2026-01-123.29x
2026-01-093.32x
2026-01-083.25x
2026-01-073.27x
2026-01-063.26x
2026-01-053.16x
2026-01-023.09x
2025-12-313.05x
2025-12-303.08x
2025-12-293.10x
2025-12-263.10x
2025-12-243.10x
2025-12-233.09x
2025-12-223.10x
2025-12-193.02x
2025-12-182.98x
2025-12-173.01x
2025-12-163.00x
2025-12-153.04x
2025-12-122.97x
2025-12-112.99x
2025-12-103.00x
2025-12-092.89x
2025-12-082.90x
2025-12-052.87x
2025-12-042.86x
2025-12-032.87x
2025-12-022.75x
2025-12-012.77x
2025-11-282.79x
2025-11-262.80x
2025-11-252.79x
2025-11-242.70x
2025-11-212.66x
2025-11-202.59x
2025-11-192.59x
2025-11-182.60x
2025-11-172.60x
2025-11-142.66x
2025-11-132.68x
2025-11-122.71x
2025-11-112.73x
2025-11-102.68x
2025-11-072.67x
2025-11-062.70x
2025-11-052.66x
2025-11-042.82x
2025-11-032.84x
2025-10-312.85x
2025-10-302.84x
2025-10-292.85x
2025-10-282.95x
2025-10-273.04x
2025-10-243.06x
2025-10-232.98x
2025-10-222.94x
2025-10-212.95x
2025-10-202.90x
2025-10-172.83x
2025-10-162.79x
2025-10-152.74x
2025-10-142.73x
2025-10-132.74x
2025-10-102.69x
2025-10-092.75x
2025-10-082.77x
2025-10-072.73x
2025-10-062.79x
2025-10-032.82x
2025-10-022.79x
2025-10-012.73x
2025-09-302.56x
2025-09-292.45x
2025-09-262.46x
2025-09-252.43x
2025-09-242.48x
2025-09-232.49x
2025-09-222.53x
2025-09-192.55x
2025-09-182.57x
2025-09-172.52x
2025-09-162.50x
2025-09-152.51x
2025-09-122.52x
2025-09-112.60x
2025-09-102.52x
2025-09-092.57x
2025-09-082.63x
2025-09-052.65x
2025-09-042.63x
2025-09-032.63x
2025-09-022.62x
2025-08-292.65x
2025-08-282.64x
2025-08-272.64x
2025-08-262.65x
2025-08-252.66x
2025-08-222.63x
2025-08-212.54x
2025-08-202.60x
2025-08-192.59x
2025-08-182.57x
2025-08-152.56x
2025-08-142.55x
2025-08-132.54x
2025-08-122.52x
2025-08-112.47x
2025-08-082.47x
2025-08-072.48x
2025-08-062.49x
2025-08-052.80x
2025-08-042.81x
2025-08-012.80x
2025-07-312.83x
2025-07-302.91x
2025-07-292.94x
2025-07-282.95x
2025-07-252.92x
2025-07-242.92x
2025-07-232.81x
2025-07-222.75x
2025-07-212.58x
2025-07-182.64x
2025-07-172.67x
2025-07-162.64x
2025-07-152.64x
2025-07-142.68x
2025-07-112.70x
2025-07-102.75x
2025-07-092.69x
2025-07-082.69x
2025-07-072.63x
2025-07-032.67x
2025-07-022.68x
2025-07-012.64x
2025-06-302.60x
2025-06-272.58x
2025-06-262.60x
2025-06-252.58x
2025-06-242.56x
2025-06-232.55x
2025-06-202.55x
2025-06-182.52x
2025-06-172.52x
2025-06-162.59x
2025-06-132.57x
2025-06-122.61x
2025-06-112.60x
2025-06-102.59x
2025-06-092.55x
2025-06-062.51x
2025-06-052.47x
2025-06-042.50x
2025-06-032.44x
2025-06-022.39x
2025-05-302.40x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster